Ribbens C, Andre B, Jaspar J M, Kaye O, Kaiser M J, De Groote D, Malaise M G
Department and Laboratory of Rheumatology, University of Liège, Belgium.
J Rheumatol. 2000 Apr;27(4):888-93.
To demonstrate that serum matrix metalloproteinase-3 (MMP-3) is a variable associated with disease activity and with the response to treatment in rheumatoid arthritis (RA).
Serum MMP-3 levels were measured and compared to biological and clinical disease activity variables in 20 patients with active RA assessed serially during a one year prospective open label trial with methotrexate or tenidap.
MMP-3 levels were significantly correlated with C-reactive protein (CRP) and interleukin 6 serum levels as well as with the disease activity score (DAS), not only at start in untreated patients but also during the 12 month followup period in both treated groups. Early changes (after 0.5, 1, 2, or 3 months) in MMP-3 levels were significantly associated with change in DAS observed 4 to 6 months later.
In addition to CRP, a systemic marker of inflammation, serum MMP-3 may serve as a consistent synovial derived marker of RA disease activity, early changes of which predict disease outcome.
证明血清基质金属蛋白酶-3（MMP-3）是类风湿关节炎（RA）中与疾病活动度及治疗反应相关的一个变量。
在一项为期一年的甲氨蝶呤或替诺哒前瞻性开放标签试验中，对20例活动期RA患者进行连续评估，测量血清MMP-3水平，并与生物学和临床疾病活动度变量进行比较。
MMP-3水平不仅在未治疗患者开始时，而且在两个治疗组的12个月随访期内，均与C反应蛋白（CRP）、白细胞介素6血清水平以及疾病活动评分（DAS）显著相关。MMP-3水平的早期变化（在0.5、1、2或3个月后）与4至6个月后观察到的DAS变化显著相关。
除了作为炎症全身性标志物的CRP外，血清MMP-3可能作为RA疾病活动度的一个持续的滑膜来源标志物，其早期变化可预测疾病转归。
